Andrew Anzalone is Head of the Prime Editing Platform at Prime Medicine, where he leads efforts to advance genome editing technologies for human therapeutic applications. Andrew received his Sc.B. degree in chemistry from Brown University, followed by his M.D. and Ph.D. degrees from Columbia University, where he completed his thesis research under the mentorship of Prof. Virginia W. Cornish. After finishing his graduate studies, Andrew moved to the Broad Institute of MIT and Harvard, where he was a Jane Coffin Childs Memorial Fund Postdoctoral Fellow in the laboratory of Prof. David R. Liu. In Prof. Liu’s lab, Andrew pioneered the development of prime editing, a novel search-and-replace gene editing technology that has the potential to correct a large fraction of human genetic variants associated with disease.